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N,N Dimethylacetamide a drug 
excipient that acts as bromodomain 
ligand for osteoporosis treatment
Chafik Ghayor1, Bebeka Gjoksi1,2, Jing Dong3, Barbara Siegenthaler1,4, Amedeo Caflisch3 & 
Franz E. Weber1,2,4
N,N-Dimethylacetamide (DMA) is a water-miscible solvent, FDA approved as excipient and therefore 
widely used as drug-delivery vehicle. As such, DMA should be devoid of any bioactivity. Here we report 
that DMA is epigenetically active since it binds bromodomains and inhibits osteoclastogenesis and 
inflammation. Moreover, DMA enhances bone regeneration in vivo. Therefore, our in vivo and in vitro 
data reveal DMA’s potential as an anti-osteoporotic agent via the inhibition of osteoclast mediated 
bone resorption and enhanced bone regeneration. Our results highlight the potential therapeutic 
benefits of DMA and the need for reconsideration of previous reports where DMA was used as an 
‘inactive’ drug-delivery vehicle.
Heritable changes in gene expression or cellular phenotype not linked to changes in the underlying DNA 
sequence are studied in epigenetics. Such changes include acetylation known to act as scaffolds for the assem-
bly of macromolecular complexes that orchestrate chromatin accessibility to transcription factors and allow the 
recruitment and activation of the RNA polymerases. The discovery of the drugability of bromodomains (BRD)1 
has fueled the development of small molecule inhibitors. Proteins that contain bromodomains are involved in the 
regulation of transcriptional programs and have been identified in oncogenic rearrangements that lead to highly 
oncogenic fusion proteins, which have a key role in the development of several aggressive types of cancer2. High 
affinity micro-molar range bromodomain inhibitors I-BET and JQ1 were developed and presented efficiency in 
vivo against LPS-induced endotoxic shock, bacteria-induced sepsis3, decrease tumor size, and enhanced survival 
in testis midline carcinoma and myelomas4.
A link between bromodomains and the immune system has been shown for Brd4 and NFĸB with its two 
subunits p50 and RelA5. The latter subunit, if acetylated, binds Brd4, which in turn enhances the transcriptional 
activation of NF-ĸB and the expression of a subset of NF-ĸB-responsive inflammatory genes. Brd2 and Brd4 
together with Brd3 and BrdT form the BET protein family of transcriptional regulators. BET proteins possess 
dual, mutually-related Bromodomains in the amino-terminal region and protein–protein interaction domains 
for association with transcription machinery in the carboxyl-terminal region, called extra terminal (ET) domain 
and a C-terminal domain (CTD)6.
Pro-inflammatory reactions have been linked to a range of chronic situations associated with aging, including 
cardiovascular disease7, diabetes8, and dementia9. There is increasing evidence involving chronic inflammation 
in osteoporosis and fracture risk in adults10,11. Osteoporosis is a skeletal disorder characterized by compromised 
bone strength associated to an increase in fracture risk. It is most often caused by osteoclastic bone resorption that 
is not sufficiently compensated for by increased bone formation by osteoblasts12.
Organic solvents are commonly used in the pharmaceutical industry as reaction media, for product synthesis 
and as drug-vehicle. DMA is FDA approved as excipient and therefore widely used as drug-delivery vehicle13. In 
high risk neuroblastoma treatment DMA, at high concentration, is administered to facilitate busulfan applica-
tion14. Busulfan is a DNA-alkylating drug applied as a myeloablative chemotherapeutic agent prior to stem cell 
transplantation in pediatric and adult patients suffering from neuroblastoma or other malignancies15. In 2009, 
we were the first to show that another FDA approved excipient: N-methyl pyrrolidone (NMP), is bioactive16,17 
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and screened other small chemicals approved by the FDA for bioactivity. From all the excipients tested, we found 
DMA to be epigenetically active, since it binds to bromodomains. Overall, our study shows that DMA alters oste-
oblast/osteoclast balance, inhibits inflammatory response and prevents estrogen depletion-induced osteoporosis. 
This study focuses on the potential therapeutic benefits of DMA in osteoporosis, bone regeneration and related 
bone diseases, and emphasizes the fact that studies where DMA or other solvents were used as controls must be 
analyzed with caution.
Results
DMA is a bromodomain ligand. A substantial portion of the bioactivity of the excipient NMP in terms of 
bone resorption and inflammation can be linked to its affinity to bromodomains18,19. To test DMA for its affinity 
to bromodomains we employed an AlphaScreen assay and studied the effect of DMA on the binding of different 
recombinant human bromodomains and recombinant human BET bromodomains. DMA inhibits the binding 
activity of BRD2 and BRD4 (Fig. 1a,c) with an IC50 value of 11 mM and 6 mM, respectively (Fig. 1b,d).
To provide further evidence of the binding of DMA to bromodomains we solved the crystal structure of the 
complex of DMA and the N-terminal bromodomain of BRD4 at 1.5 Å resolution (PDB code 5HCL). The X-ray 
structure shows that DMA occupies the acetyl lysine binding site (Fig. 1e; Table 1) and is an acceptor in a hydro-
gen bond with the side chain of the evolutionary conserved Asn140. Despite the fact that DMA concentrations 
needed for bromodomain inhibition are in the mM-range, this effect is meaningful since during busulfan admin-
istration, DMA concentrations found in serum ranges between 3.09 and 8.77 mM20.
DMA for osteoporosis treatment. In bone, inhibition of BRD4 stops differentiation to osteoclasts21,22, the 
cells responsible for bone degradation. To test DMA for its potential to preserve bone tissue and for osteoporosis 
treatment, an ovariectomy (OVX) model in rodents was employed and DMA was administered by i.p. injec-
tions, resulting in a weekly peak concentration of 6 mM. Menopause is often accompanied by weight gain due to 
estrogen deficiency. We found ovariectomy promoted a significant increase in body mass (Fig. 2a) and enhanced 
marrow lipid accumulation within bone marrow (Fig. 2b) while DMA reversed these effects.
The estradiol level in the OVX Veh group was significantly lower than in Sham Veh group (Fig. 3a). DMA was 
not able to rescue estradiol levels and therefore acts independent of estradiol levels. Analysis of the bone turnover 
marker osteocalcin revealed an increase in the OVX vehicle group compared with those in Sham vehicle group 
which was prevented when the OVX group was treated with DMA (Fig. 3b). Static histomorphometry analysis 
Figure 1. DMA acts as a low-affinity bromodomain inhibitor. DMA effect on the binding ability of 
bromodomains and BET bromodomains (a): effect 10 mM DMA on the binding ability of recombinant BRD2 
using the AlphaScreening assay (n = 2 + 2). (b) Determination of millimolar half-maximum inhibitory 
concentration (IC50) for DMA on BRD2. (c) Effect 10 mM DMA on the binding ability of recombinant 
BRD4 using the AlphaScreening assay (n = 2 + 2). (d) Determination of millimolar half-maximum inhibitory 
concentration (IC50) for DMA on BRD4 binding activity. (e) Crystal structure of DMA (sticks) bound to 
BRD4-BD1 (PDB code 5HCL). P values were determined by Mann-Whitney- U Test.
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of femurs (Fig. 3c) revealed that DMA treatment prevents bone loss in OVX compared to the control group. The 
color coded thickness map of the local diameter of pores devoid of trabeculae in the femur revealed an increase 
in diameters of pores in the OVX sham group and confirmed that DMA treatment preserves bone architecture in 
the OVX-treated group (Fig. 3d).
Compound DMA
Bromodomain BRD4
Data collection
Space group P 21 21 21
Unit cell
 a (Å) 37.62
 b (Å) 43.83
 c (Å) 78.46
 alpha (°) 90
 beta (°) 90
 gamma (°) 90
 Resol. range (Å) 39.23–1.50
 Unique reflections 21250 (3002)
 <I/σ(I)> 42.5 (28.2)
 R merge 0.031 (0.045)
 Completeness (%) 99.2 (98.1)
 Multiplicity 6.5 (6.2)
Refinement
 Resol. range (Å) 39.23–1.50
 R factor/R free 14.52/17.54
 Mean B factors (A2) 12.50
 RMS bonds (Å) 0.0057
 RMS angles (°) 0.820
Table 1.  Atomic coordinates and structure factors of BRD4 in complex with DMA as deposited into the 
Protein Data Bank as entry 5HCL.
Figure 2. Effects of DMA rat weight and lipid accumulation within bone marrow. Body weight gain (a) over 
15 weeks of treatment. Data are the mean ± SD values (N = 6 per group from 2 independent experiments). OVX 
vehicle group is significantly different from the Sham vehicle at all time points (P = 0.001). OVX vehicle group is 
significantly different from the OVX DMA group. P values are indicated in the figure. H&E staining (b) of distal 
femur showing the effects of ovariectomy and DMA treatment on marrow lipid accumulation. P values were 
determined by Mann-Whitney- U Test.
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Moreover, micro-CT scans indicate that OVX resulted in the deterioration of trabecular bone microarchitec-
ture, supported by the reduced bone volume to total volume (BV/TV) and trabecular number (Tb.N) in compari-
son with the Sham group (Fig. 3e). In contrast, trabecular spacing (Tb.Sp) was significantly increased in response 
to OVX compared to the Sham group. DMA treatment significantly improved the microarchitecture deterioration 
mentioned above, but DMA was not able to reverse these parameters to a similar degree as in the Sham Veh 
group. Cortical bone parameters appeared unaffected.
Bone degradation and bone regeneration. Next we assessed the effect of DMA on bone degrading 
osteoclast and bone forming osteoblast differentiation and maturation. At the cellular level, DMA appears to 
inhibit maturation of osteoclasts induced by RANKL since in the presence of DMA less giant multinucleated oste-
oclasts formed (Fig. 4a,b) and cellular activity of osteoclasts determined by tartrate resistant alkaline phosphatase 
(TRAP) activity was decreased (Fig. 4c). To investigate the effect of DMA on bone formation we employed a 
guided bone regeneration model and delivered DMA via a biodegradable membrane23. Significantly more bone 
formed in this non-critical size defect when the membrane was loaded with DMA, compared to membrane alone 
(Fig. 4d,e). Therefore, DMA enhanced bone regeneration and bone formation in vivo.
In an osteoblast differentiation model where multipotent cells are differentiated to osteoblasts by bone mor-
phogenetic protein-2 (BMP2), monitored by an increase in alkaline phosphatase activity (ALP), we saw that 
osteoblast differentiation determined by ALP was enhanced by the low affinity bromodomain inhibitor DMA 
Figure 3. DMA prevents bone deterioration induced by estrogen depletion in rats. Changes of serum levels 
of estradiol after ovariectomy (a). The results of the Sham group were compared with OVX Veh group, and 
the results of the OVX DMA group were compared with the results of OVX Veh. Data are mean ± s.d. Two 
independent experiments were performed with 3 animals each (n = 6). Changes of serum levels of osteocalcin 
after ovariectomy (b). The results of the Sham group were compared with OVX Veh group, and the results of 
the OVX DMA group were compared with the results of OVX Veh. Data are mean ± s.d. Two independent 
experiments were performed with 3 animals each (n = 6). Goldner’s Trichrome staining of distal femur (c) show 
the effects of ovariectomy and DMA treatment on the histomorphometric parameters. Micro-CT analysis (d)  
illustrates the effects of DMA on bone loss induced by estrogen depletion. 3D image and color coded thickness 
map of the local diameter of the pores devoid of trabeculae. Bone parameters (e) were analyzed by micro-CT 
after 15 weeks of DMA treatment in OVX rats. Graphs represented bone volume (BV/TV), trabecular 
separation (Tb. Sp), trabecular number (Tb. N), and trabecular thickness (Tb. Th). Data are mean ± s.d. (n = 6 
per group). P values are provided. P values were determined by Mann-Whitney- U Test.
www.nature.com/scientificreports/
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(Fig. 5a,b). The same applies to pre-osteoblastic cells (Fig. 5c). The high affinity bromodomain inhibitor JQ1, 
however, inhibited BMP2-induced differentiation to osteoblasts (Fig. 5a) and is known to interfere with osteoblast 
differentiation by inhibition of Runx2 expression21. The low affinity bromodomain inhibitor DMA overcomes 
and even enhances bone formation in vivo and in vitro (Figs 4d,e and 5a) since it not only acts as bromodomain 
inhibitor but also as enhancer of BMP activity by increasing Smad1/5/8 and p38 phosphorylation (Fig. 5d, S1).
DMA and inflammation.  To address inflammation, as the third aspect of osteoporosis, we investigated 
the effect of DMA on the TNF-α inhibition of BMP-induced osteogenesis. BMP2-induced ALP activity was 
decreased by TNF-α treatment. Pretreatment with DMA not only abolished the inhibitory effect of TNF-α but 
also potentiated the effect of BMP-2 dose dependently (Fig. 6a).
To further analyze the inflammatory process, we stimulated RAW264.7 macrophages with lipopolysaccharide 
(LPS), causing an accumulation of nitric oxide (NO), a characteristic feature of activated macrophages (Fig. 6b). 
DMA alone had no effect on NO production. DMA pretreatment, however, suppressed LPS-induced NO produc-
tion in a dose-dependent manner. The change of iNOS expression, the enzyme responsible for NO production, 
was examined and iNOS was induced with LPS treatment and this induction was diminished substantially by 
DMA both at the protein and mRNA level (Fig. 6c).
Since nuclear factor-κB (NF-κB) is involved in the transcriptional regulation of cytokines and targeted by 
bromodomain inhibitors, we examined the nuclear translocation of p65 which tightly linked to NFκB activa-
tion. In essence, we analyzed the cellular location changes of NF-κB/p65 after LPS stimulation with or without 
DMA pre-treatment (Fig. 5d). In unstimulated cells NF-κB/p65 was located in the cytoplasm. In LPS-treated cells 
Figure 4. DMA inhibits osteoclast differentiation and enhances bone regeneration. Effects of DMA on 
osteoclast differentiation (a). Microscopic view of MNCs after TRAP staining. Number of multinucleated 
cells (MNCs) (b) were determined after 6 days of treatment. RAW264.7 cells were seeded on a 24-well culture 
plate and treated with RANKL alone or with different concentrations of DMA as indicated. After 6 days of 
incubation, TRAP activity was measured as described under “methods”. Data are expressed as the mean ± s.d. 
(n = 6) from a representative experiment. In parallel, cells were stained for TRAP after differentiation into 
mature osteoclasts and MNCs were counted under microscope. TRAP activity (c) was determined after 6 days 
of treatment. In parallel, cells were stained for TRAP after differentiation into mature osteoclasts and MNCs 
were counted under microscope. Effects of DMA on bone regeneration (d). Non-critical size defects were 
generated in calvarial bones of rabbits and treated with a biodegradable membrane with or without DMA. After 
4 weeks, bone regeneration within the defect was evaluated based on the middle cross-sections. The original 
defects are indicated by the square. Bone appears magenta/green in the Goldner’s-Trichrome stained sections. 
Histomorphometric analysis (e) revealed significantly greater bone regeneration when the membrane contained 
DMA than the same membrane without DMA. (n = 6). P values were determined by Mann-Whitney- U Test.
www.nature.com/scientificreports/
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NF-κB/p65 translocated into the nucleus and pre-treatment with DMA partially suppressed the LPS-induced p65 
translocation, suggesting that DMA inhibits the LPS-induced NF-κB activation. Macrophages orchestrate the 
immune response, hematopoiesis, and other homeostatic processes via cytokine expression and release. mRNA 
expression of IL-1α, IL-1β, IL-6 and TNF-α were markedly up-regulated after LPS stimulation, however, signifi-
cantly reduced by DMA pretreatment (Fig. 6e).
Discussion
Therapeutic agents targeting protein expression on the epigenetic level have shown encouraging antitumor 
activity. Bromodomain inhibitors decrease the expression of oncogenes like myc and Runx221,24–27 and are pres-
ently being tested in clinical trials. Recent studies demonstrated that JQ1, a potent inhibitor of BRD2, BRD3, 
BRD4, and BET proteins, beside its antitumor activity suppress inflammation by a reduction of the inflammatory 
cytokine release, bone destruction by the inhibition of osteoclast maturation and bone formation by the inhi-
bition of osteoblast maturation21,22. The activities of JQ1 in suppression of inflammation and the inhibition of 
osteoclast maturation were sufficient for a short term treatment of periimplantitis22. For long-term treatment of 
osteoporosis, however, the use of JQ1 could compromise the treatment due to its inhibiting effect on osteoblast 
maturation21.
In the present study, we showed that DMA preserves bone mass and architecture in a postmenopausal osteo-
porosis model based on estrogen deficiency (Fig. 3) and thus has the potential to treat and prevent osteoporosis. 
DMA was proved to be a ligand for bromodomains (Fig. 1) and shares with JQ1 the potential to reduce the 
inflammatory cytokine release and to inhibit osteoclast maturation (Fig. 4a–c). In contrast to the high affinity bro-
modomain ligand JQ1, the low affinity ligand DMA, however, was shown here to enhance osteoblast maturation 
induced by BMP-2 in vitro and bone regeneration in vivo even without the application of recombinant BMP-2 
(Fig. 4d,e and 5). Although BRD4 bromodomain inhibition is associated with the reduction of Runx2 expression 
needed for osteoblast differentiation, the lower affinity of DMA to BRD4 and the additional activity of enhancing 
the kinase activity of the BMP-2 receptor for Smads and p38 overcomes the reduced Runx2 expression. At the 
bottom line, DMA even enhances bone regeneration and osteoblast maturation in vivo (Fig. 4d,e).
Chronic inflammation plays an important role in the development of several diseases such as rheumatoid 
arthritis (RA) and osteoporosis. Both pathologies are associated with increased risk of fractures and systemic 
bone loss. Since bone loss is related to the activation of TNF-α system, it can be hypothesized that TNF-α directly 
controls osteoblast survival and/or function in addition to its induction of osteoclast differentiation leading to 
Figure 5. DMA improves BMP-2 induced osteoblast differentiation. Effects of DMA on osteoblast 
differentiation (a). Alkaline phosphatase activity was measured in multipotent C2C12 cells, which do not 
produce autologous BMP. C2C12 cells treated with BMP2 alone or with either DMA (5 mM) or JQ1 (5 μM) 
in the presence of BMP2. After 6 days of stimulation, ALP activity was measured (n = 6). To examine alkaline 
phosphatase activity histochemically, multipotent C2C12 cells stimulated with BMP-2 in the presence of DMA 
(b). Alkaline phosphatase activity was also measured in pre-osteoblast cell line, MC3T3-E1 (c) (N = 6). Effect 
of DMA on Smad and MAPK signaling (d). C2C12 cells were stimulated as indicated, and whole cell extracts 
were separated by SDS-PAGE, transferred to PVDF membranes, and probed with anti-phospho-Smad 1/5/8, 
anti-phospho-MAPK (Erk, Jnk and p38) antibodies. Anti-actin antibody was used as a loading control. The 
experiment was repeated 3 times and a representative blot is displayed (Original blots are shown in Figure S1). P 
values were determined by Mann-Whitney- U Test.
www.nature.com/scientificreports/
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excess of bone resorption28. This can also explain the association between inflammation and osteoporosis29. The 
suppressive effect of DMA on inflammation has been discovered and patented in 196230. In our study we propose 
the molecular mechanism of this effect and suggest that DMA exerts its anti-inflammatory activity as competitor 
of bromodomain binding (Fig. 1). The effect of DMA on the inflammatory process (Fig. 6) in particular mediated 
by NFκB-dependent mechanisms is not unexpected since inhibitors of bromodomain have shown therapeu-
tic promise in several diseases including inflammation-related ones31. For the long-term treatment of chronic 
inflammatory diseases DMA has the advantage of non-interference with bone formation and regeneration, for 
acute inflammatory diseases like sepsis, high affinity bromodomain inhibitors like JQ1 are certainly more effec-
tive. Moreover, DMA reduced the weight of the ovariectomized animals and the fat content in the marrow which 
points to the potential of DMA to be used for adiposity treatment (Fig. 2). The same was reported for JQ1 with 
weight loss being the sole side effect of JQ1 application for contraception in male mice32.
The preclinical data presented in this study establish the potential of low affinity bromodomain inhibitors like 
DMA for long term treatments as needed in osteoporosis, adiposity, or chronic inflammation related diseases. 
DMA is FDA approved and presents no toxic effect in human. In fact, it has been reported that DMA, when used 
as a vehicle for intravenous busulfan, does not produce adverse effects in pediatric oncologic patients at doses 
even higher than those shown to suppress inflammation33. The concentration, however, needed for effect is in the 
millimolar range. Therefore, clinical long term studies will be required to understand these risks in more detail.
Figure 6. DMA opposes deleterious effect of TNF-α on osteoblast differentiation and inhibits LPS-induced 
inflammatory process. Effect of DMA on Alkaline phosphatase activity (a) was measured in multipotent 
C2C12 cells stimulated with BMP-2 in the presence of TNF-α and TNF-α + DMA. Effect of DMA on nitric 
oxide (NO) production and iNOS expression (b). RAW264.7 cells were incubated with 1 μg/ml LPS with or 
without DMA for 48 h. Data are expressed as mean ± s.d. (n = 6). For iNOS expression analysis (c), RAW264.7 
cells were treated with LPS (1 μg/ml) in the absence or presence of DMA, total RNA (6 h after stimulation) 
or whole cell lysates (48 h after stimulation) were isolated. iNOS mRNA levels were determined by real-time 
PCR and normalized to GAPDH level and expressed as ΔΔCT. Whole cell lysates were subjected to Western 
blot analysis with antibody against iNOS (Original blots are shown in Figure S2). Data are expressed as 
mean ± s.d. (n = 6). Effect of DMA on NF-κB translocation (d). RAW264.7 cells were grown on 15 μ-Chamber 
12 well (Ibidi, Martinsried, Germany), stimulated with LPS, and LPS after DMA pre-treatment (LPS + DMA). 
After 30 min stimulation, cells were fixed in 4% paraformaldehyde for 15 min at room temperature, and the 
subcellular localization of the NF-kB p65 subunit was shown by immunofluorescence staining. Nuclei were 
counterstained with Hoechst (Sigma-Aldrich). Effect of DMA on LPS-induced pro-inflammatory cytokines (e).  
RAW264.7 cells were treated with LPS (1 μg/ml) in the absence or presence of DMA, and total RNA was 
isolated 6 h after treatment. IL-1α, IL-β, TNF-α, and IL-6 mRNA levels were determined by real-time PCR and 
normalized to GAPDH level Results are expressed as ΔΔCT. Data are expressed as mean ± s.d. (n = 6) and P 
values provided. P values were determined by Mann-Whitney- U Test.
www.nature.com/scientificreports/
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We conclude that DMA functions as bromodomain inhibitor and BMP enhancer and displays a potential 
role as an anti-osteoporotic drug based on its triple effect: inhibition of osteoclastogenesis, enhancement of oste-
oblastogenesis, in combination with its anti-inflammatory activity. Agents that modulate or inhibit epigenetic 
modifications have shown great potential in inhibiting the progression of many diseases. Given the effectiveness 
of DMA, there is great potential for the development of novel therapeutics with DMA as direct or adjuvant ther-
apeutic compound for bone related diseases.
Methods
AlphaScreening assay. AlphaScreening assay was performed as previously described19. The percent inhibi-
tion in the presence of DMA was calculated according to the following equation: % inhibition =100 - % activity. 
The IC50 value was determined by the concentration causing a half-maximal percent activity.
Bromodomain expression and purification.  Briefly, His-tagged BRD4 (residues 42–168, BRD4-BD1) 
was expressed in Escherichia coli BL21 (DE3) cells upon induction with isopropyl thio-beta-D-galactoside 
(IPTG, final concentration 0.1 mM) for 16 h at 18 °C. Bacteria were lysated and the His-tagged proteins were 
purified on HisTrap columns (GE Healthcare) and eluted using a step gradient of imidazole. The poly-Histidine 
tags were removed by overnight incubation with His-tagged tobacco etch virus (TEV) protease purified in-house. 
A size-exclusion chromatography step (HiLoad 16/600 Superdex75 column) and a Ni-affinity chromatography 
step were subsequently performed to finally purify the cleaved bromodomains. Samples were then concentrated, 
flash frozen and stored at −80 °C.
X-ray crystallography, Data Collection, and Structure Determination (PDP code 5HCL).  Apo 
crystals of the BRD4-BD1 bromodomain were grown at 4 °C using the hanging drop vapor diffusion method 
under the condition 0.2 M Sodium Nitrate, 20% PEG 3350, 10% ethylene glycol. The apo crystals were then 
soaked with 10% (V/V) DMA overnight and flash-frozen for measurements. Data sets were collected on 
a PILATUS 16 M detector at the Swiss Light Source beamline X06SA of the Paul Scherrer Institute (Villigen, 
Switzerland) and indexed, integrated and scaled with the XDS34 and CCP4 programs35. The structures were solved 
by molecular replacement with PHASER36 using the BRD4 structure (PDB entry 4PCI) as a search model and 
refined with PHENIX37. The atomic coordinates and structure factors of BRD4 in complex with DMA have been 
deposited into the Protein Data Bank as entry 5HCL.
Data collection and refinement statistics are given (Table 1).
Animal experiments. All animal procedures were approved by the Animal Ethics Committee of the local 
authorities (Canton Zurich, 40/2012; 108/2012) and performed in accordance with the ethics criteria con-
tained in the bylaws of the Institutional Animal Care and Use Committee. After the acclimatization period, the 
animals (female, 15 weeks old, Sprague Dawley) were randomly bilaterally ovariectomized (OVX, n = 12) or 
sham-operated (Sham, n = 6). One week after surgery, the OVX rats were divided into 2 groups: OVX with vehi-
cle (OVX Veh, n = 6) and OVX with DMA (OVX DMA, n = 6). Treatment was initiated 1 week after OVX and 
lasted for 15 weeks. DMA was administered once a week via i.p. injections (92 μl DMA plus 108 μl PBS per 100 gr. 
rat). The n of 6 derived from 2 independent experiments with n = 3 each. Sample size was determined by power 
analysis. Whole blood sample was collected via abdominal aorta puncture immediately following sacrifice by CO2 
asphyxiation. Then, a serum specimen was harvested after centrifugation (2000 rpm for 20 min) and stored at 
-80 °C until further analysis. Femurs were dissected and the adherent tissue removed before placing the samples 
in 70% ethanol and later used for micro-CT analysis and measurement of bone parameters. Bone regeneration 
was tested in a guided bone regeneration model at the calvarial bone of 6 rabbits (female, 26 week old, New 
Zealand white rabbit) as described earlier23. DMA loading of the membrane was performed by vapor deposition 
to yield 10% weight increase23. Sample size was determined by power analysis.
Histology. Paraffin- and methacrylate-based histology was performed as previously described19.
Serological Analysis of Bone Markers.  Serum markers were analyzed to monitor the treatment effect on 
bone physiology as previously described19.
Microcomputer Tomography Analysis (μCT). The rat femur samples were measured with a cone-beam 
microCT (μCT 100, SCANCO MEDICAL AG, Brüttisellen, Switzerland) as previously described19. The param-
eters were: bone volume over total volume (BV/TV), trabecular number (Tb.N), trabecular separation (Tb.Sp), 
and trabecular thickness (Tb.Th).
Cell Cultures. RAW264.7, C2C12 and MC3T3-E1 cells were purchased from American Type Culture 
Collection (ATCC). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (C2C12 and 
RAW264.7) or alpha-minimal essential medium (MC3T3-E1) and treated as described previously38,39. All cell 
experiments were performed 2 times independently with an n = 3 to yield an overall n of 6. Sample size for cells is 
fixed at n = 6 based on our experience. All cell lines were mycoplasma tested via pcr (Promokine Kit).
ALP activity assay and ALP staining.  Alkaline phosphatase (ALP) was used as a marker of osteoblastic 
differentiation. ALP activity and ALP staining were evaluated as described previously17. Briefly, cells were seeded 
in 24-well plates (n = 6 per group). One day later, cells were incubated with BMP2 in the presence or absence of 
DMA for 6 days. After incubation, ALP activity was measured on whole cell extract using p-nitrophenylphosphate 
(Sigma) as a substrate. To examine alkaline phosphatase activity histochemically, cells were fixed for 10 min with 
www.nature.com/scientificreports/
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3.7% formaldehyde at room temperature. After washing with PBS, the cells were stained as described in40. Images 
of stained cells were captured with a CDD camera.
Western blot analysis. Treated cells were rapidly frozen in liquid nitrogen and stored at - 80 °C until used 
for analysis as previously described38,39.
TRAP activity, TRAP staining, Nitrite determination, Quantitative real-time PCR (qPCR), and 
Nuclear translocation of p65.  All these methodologies were performed as previously described16,41.
Statistical analysis. All statistical analysis were performed with IBM SPSS statistics 22. Results are 
expressed as the mean ± SD and were compared by the non-parametric Kruskal-Wallis-Test followed by the 
Mann-Whitney- U Test. Results were considered significantly different for P < 0.05.
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